Odalasvir: Phase IIa started

Johnson & Johnson began an open-label Phase IIa trial to evaluate a once-daily oral regimen of Olysio/ Sovriad simeprevir, AL-335 and odalasvir for 4, 6 or 8 weeks in about 60 patients. J&J’s Janssen Biotech Inc. unit has exclusive, worldwide rights to develop and commercialize HCV products and regimens containing >=1 HCV asset from Achillion, including odalasvir (see BioCentury, May 25). J&J’s AL-335 is a uridine-based nucleotide analog inhibitor of HCV NS5B polymerase. ...